Gene · 2348
Papers3,253
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 3,253
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimen. | Br J Clin Pharmacol | 2025 | 39307840 | PubTator, text mining | PubMed |
| Folate Receptor Immunohistochemical Staining and Gynecologic Tumors: Initial Experience With 216 Cases. | Int J Gynecol Pathol | 2025 | 38914019 | PubTator, text mining | PubMed |
| Folate Receptor Alpha Expression and the Tumor Immune Microenvironment in Patients with Cervical Cancer. | Int J Gynecol Pathol | 2025 | 38914017 | PubTator, text mining | PubMed |
| Targeted drug conjugates in cancer therapy: Challenges and opportunities. | Pharm Sci Adv | 2024 | 41550162 | PubTator, text mining | PubMed |
| pH-responsive bond as a linker for the release of chemical drugs from RNA-drug complexes in endosome or lysosome. | RNA Nanomed | 2024 | 40115434 | PubTator, text mining | PubMed |
| Identification of Transcriptional Regulators of Immune Evasion Across Cancers: An Alternative Immunotherapeutic Strategy for Cholangiocarcinoma. | Cancers (Basel) | 2024 | 39766097 | PubTator, text mining | PubMed |
| Mirvetuximab Soravtansine in solid tumors: A systematic review and meta-analysis. | PLoS One | 2024 | 39729462 | PubTator, text mining | PubMed |
| [DNA Methylation Profiling in Aneurysm and Comorbid Atherosclerosis of the Ascending Aorta]. | Mol Biol (Mosk) | 2024 | 39707852 | PubTator, text mining | PubMed |
| Efficacy and Safety of Farletuzumab in Ovarian Cancer: A Systematic Review and Single-Arm Meta-Analysis. | Cureus | 2024 | 39677200 | PubTator, text mining | PubMed |
| Proteomics analysis of extracellular vesicles for biomarkers of autism spectrum disorder. | Front Mol Biosci | 2024 | 39606031 | PubTator, text mining | PubMed |
| Deciphering Folate Receptor alphaGene Expression and mRNA Signatures in Ovarian Cancer: Implications for Precision Therapies. | Int J Mol Sci | 2024 | 39596024 | PubTator, text mining | PubMed |
| Folate Receptor Alpha-A Secret Weapon in Ovarian Cancer Treatment? | Int J Mol Sci | 2024 | 39595996 | PubTator, text mining | PubMed |
| Identification and Characterization of Fully Human FOLR1-Targeting CAR T Cells for the Treatment of Ovarian Cancer. | Cells | 2024 | 39594628 | PubTator, text mining | PubMed |
| Concurrent High-Grade Serous Carcinoma with Mucinous Differentiation and Ectopic Complete Molar Pregnancy of the Fallopian Tube: A Case Report. | Ann Clin Lab Sci | 2024 | 39537224 | PubTator, text mining | PubMed |
The Efficacy and Safety of Folate Receptor α-Targeted Antibody-Drug Conjugate Therapy in Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta-Analysis. | Cancer Med | 2024 | 39526448 | PubTator, text mining | PubMed |
| Targeted protein degradation: advances in drug discovery and clinical practice. | Signal Transduct Target Ther | 2024 | 39500878 | PubTator, text mining | PubMed |
| Combination therapy of Sanjie Zhentong capsules for endometriosis: Impact on hormone regulation and serum expression of FOLR1 and MSLN. | Medicine (Baltimore) | 2024 | 39465861 | PubTator, text mining | PubMed |
| Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary. | Gynecol Oncol | 2024 | 39461270 | PubTator, text mining | PubMed |
| Assessment of mirvetuximab soravtansine immunogenicity in patients with folate receptor alpha-positive ovarian cancer. | Bioanalysis | 2024 | 39378056 | PubTator, text mining | PubMed |
| ADC: a deadly killer of platinum resistant ovarian cancer. | J Ovarian Res | 2024 | 39367438 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2348/papers?page=16